Results 201 to 210 of about 28,722 (228)

mTORC2 Phosphorylation of GSDME‐N Drives Cullin4B‐Mediated Proteasomal Degradation to Suppress Pyroptosis and Confer Radioresistance in Small Cell Lung Cancer

Advanced Science, EarlyView.
Radioresistance severely limits the efficacy of therapies for small cell lung cancer (SCLC). This study reveals a novel mechanism of resistance driven by the active suppression of pyroptosis. Specifically, the mTORC2 complex directly phosphorylates GSDME‐N and promotes its CUL4B‐mediated ubiquitination and proteasomal degradation.
Qing‐qing Xu, Ci‐ming Sun, Sui‐xian Zhang, Rui Li, Chen‐fei Wu, Zai‐shan Lin, Li Li, Run‐zhe Chen, Qi‐wen Li, Yuan‐yuan Chen, Xuan Li, Ming Chen   +11 more
wiley   +1 more source

A Sprayable Nanoplatform Breaks the Vicious Cycle of Diabetic Wounds via Photoactivated Antioxidant and Drug Delivery

Advanced Science, EarlyView.
A sprayable near‐infrared‐activated nanoplatform incorporating MXene, ZnHCF nanozyme, and deferoxamine efficiently breaks the vicious cycle of diabetic wounds. Upon irradiation, interfacial electron transfer and photothermal effects enhance multi‐enzyme activity, enabling explosive ROS elimination, alleviation of hypoxia, and controlled DFO release ...
Jiahao Guo, Yuanyuan Meng, Qixiang Gui, Xi‐Tao Yang, Yong Fan, Xiaodong Zhu   +5 more
wiley   +1 more source

NIR‐II‐Trackable LYTACs Phyto‐Nanotheranostics for Source‐Microenvironment Dual‐Track ROS Regulation in Acute Gouty Arthritis

Advanced Science, EarlyView.
The TPR‐LYTACs nanomaterial offers a dual‐pathway strategy for precise gouty arthritis treatment by targeting and degrading the ROS‐producing enzyme NOX2 inside macrophages while its antioxidant core clears accumulated ROS outside. This “source inhibition and microenvironment scavenging” approach, guided by NIR‐II imaging, effectively controls local ...
Jian Zhang, Yingying Wang, Lujie Yu, Chunmei Jiang, Haoyu Liu, Yaohua Chen, Shutong Wu, Qin Liu, Lingling Wei, Xiaochun Zheng, Huifang Hao, Mengting Gao, Weiwei Kang, Rong Dai, Ziliang Zheng, Ruiping Zhang   +15 more
wiley   +1 more source

Cap-independent co-expression of dsRNA-sensing and NF-κB pathway inhibitors enables tunable self-amplifying RNA expression with reduced immunotoxicity

Lim TK, Ritoux A, Paine LW, Ferguson L, Abdul T, Grundy LJ, Smith ESJ.   +6 more
europepmc   +1 more source

Polymeric and lipid nanoparticles for delivery of self-amplifying RNA vaccines

Journal of Controlled Release, 2021
Self-amplifying RNA (saRNA) is a next-generation vaccine platform, but like all nucleic acids, requires a delivery vehicle to promote cellular uptake and protect the saRNA from degradation. To date, delivery platforms for saRNA have included lipid nanoparticles (LNP), polyplexes and cationic nanoemulsions; of these LNP are the most clinically advanced ...
Anna K Blakney, Paul F Mckay, Kai Hu
exaly   +4 more sources

Innate Inhibiting Proteins Enhance Expression and Immunogenicity of Self-Amplifying RNA [PDF]

Molecular Therapy, 2021
Self-amplifying RNA (saRNA) is a cutting-edge platform for both nucleic acid vaccines and therapeutics. saRNA is self-adjuvanting, as it activates types I and III interferon (IFN), which enhances the immunogenicity of RNA vaccines but can also lead to inhibition of translation.
Anna K Blakney, Paul F Mckay, Clement Bouton   +2 more
exaly   +4 more sources

Some of the next articles are maybe not open access.

Related searches:

Polyplex nanomicelle delivery of self-amplifying RNA vaccine

Journal of Controlled Release, 2021
Self-amplifying RNA (SaRNA) is a burgeoning platform that exploits the replication machinery of alphaviruses such as Venezuelan equine encephalitis (VEE) virus or Sindbis virus (SIN). SaRNA has been used for development of human vaccines, but has not been evaluated for porcine vaccine development.
Yi-Hao Chang, Mei-Wei Lin
exaly   +3 more sources

Self-amplifying RNA virus vectors: clinical applications in cancer drug delivery [PDF]

Expert Opinion on Drug Delivery, 2019
Kenneth Lundström
exaly   +3 more sources

The role of helper lipids in optimising nanoparticle formulations of self-amplifying RNA

Journal of Controlled Release
Lipid nanoparticle (LNP) formulation plays a vital role in RNA vaccine delivery. However, further optimisation of self-amplifying RNA (saRNA) vaccine formulation could help enhance seroconversion rates in humans and improve storage stability. Altering either the ionisable or helper lipid can alter the characteristics and performance of formulated saRNA
David J Peeler, Karnyart Samnuan, Suzanne Day   +2 more
exaly   +4 more sources

Self-amplifying RNA COVID-19 vaccine

Cell
In November 2023, Japan's Ministry of Health, Labour and Welfare granted regulatory approval of ARCT-154, a self-amplifying RNA COVID-19 vaccine developed by Arcturus Therapeutics. Clinical trials showed comparable safety and efficacy using a lower dose compared to the mRNA vaccine BNT162b2. To view this Bench-to-Bedside, open or download the PDF.
Christopher J, Wayne, Anna K, Blakney
openaire   +2 more sources